Nasdaq

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...
Seeking Alpha

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients two years of age ...
Morningstar

First PRIZM Study Participant Enrolled in Tisento Therapeutics’ Open-Label Extension Study in MELAS

CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the first participant has enrolled in the company’s open-label extension study in MELAS (Mitochondrial ...
Business Insider

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause ...
Morningstar

Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior

247 patients (mean age 14.3±7.6 years) were enrolled from study sites in North America, Europe, and Australia, with a median fenfluramine exposure of 364 days (range: 19–537) and a mean daily dose of ...
Healio

Long-term data on selexipag for PAH reveal 60% survival rate at 10 years

Please provide your email address to receive an email when new articles are posted on . Researchers used data from the GRIPHON study and open-label extension study. The median selexipag dose was 1,000 ...
The American Journal of Managed Care

Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study

Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...
Business Wire

Alzprotect Announces Supportive Results from Open-Label Extension of Phase 2a Study for Progressive Supranuclear Palsy (PSP)

LILLE, France--(BUSINESS WIRE)--Alzprotect, a French biopharmaceutical company, is pleased to announce the successful completion of the open-label extension (OLE) phase following the Phase 2a clinical ...
Business Wire

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and ...